Skip to main content
AAN.com
Articles
November 1, 1983

Rating neurologic impairment in multiple sclerosis
An expanded disability status scale (EDSS)

November 1983 issue
33 (11) 1444

Abstract

One method of evaluating the degree of neurologic impairment in MS has been the combination of grades (0 = normal to 5 or 6 = maximal impairment) within 8 Functional Systems (FS) and an overall Disability Status Scale (DSS) that had steps from 0 (normal) to 10 (death due to MS). A new Expanded Disability Status Scale (EDSS) is presented, with each of the former steps (1,2,3 … 9) now divided into two (1.0, 1.5, 2.0 … 9.5). The lower portion is obligatorily defined by Functional System grades. The FS are Pyramidal, Cerebellar, Brain Stem, Sensory, Bowel & Bladder, Visual, Cerebral, and Other; the Sensory and Bowel & Bladder Systems have been revised. Patterns of FS and relations of FS by type and grade to the DSS are demonstrated.

Get full access to this article

View all available purchase options and get full access to this article.

Information & Authors

Information

Published In

Neurology®
Volume 33Number 11November 1983
Pages: 1444
PubMed: 6685237

Publication History

Published online: November 1, 1983
Published in print: November 1983

Permissions

Request permissions for this article.

Authors

Affiliations & Disclosures

John F. Kurtzke, MD
Neurology Service, Veterans Administration Medical Center and Departments of Neurology and of Community Medicine, Georgetown University School of Medicine, Washington, DC.

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. A translational MRI approach to validate acute axonal damage detection as an early event in multiple sclerosis, eLife, 13, (2024).https://doi.org/10.7554/eLife.79169
    Crossref
  2. Monitoring of the pharmacological treatment availability in patients with multiple sclerosis in the Greater Poland population, Rheumatology, 61, 6, (473-480), (2024).https://doi.org/10.5114/reum/177143
    Crossref
  3. Frequency and characteristics of chronic fatigue syndrome in multiple sclerosis patients at a university hospital in Eastern Saudi Arabia, Journal of Family and Community Medicine, 31, 1, (63-70), (2024).https://doi.org/10.4103/jfcm.jfcm_73_23
    Crossref
  4. COVID-19 Vaccination Coverage and Associated Factors in Patients with Multiple Sclerosis, Vaccines, 12, 2, (126), (2024).https://doi.org/10.3390/vaccines12020126
    Crossref
  5. Associations between Mediterranean Diet Adherence, Quality of Life, and Mental Health in Patients with Multiple Sclerosis: A Cross-Sectional Study, Journal of Personalized Medicine, 14, 2, (199), (2024).https://doi.org/10.3390/jpm14020199
    Crossref
  6. Insomnia, Fatigue, Bladder Disorders and Mood Disorders among Polish Patients with Multiple Sclerosis: Cross-Sectional Study, Journal of Clinical Medicine, 13, 4, (1043), (2024).https://doi.org/10.3390/jcm13041043
    Crossref
  7. Relapses and Serious Infections in Patients with Neuromyelitis Optica Spectrum Disorder Treated with Rituximab: A Swedish Single-Center Study, Journal of Clinical Medicine, 13, 2, (355), (2024).https://doi.org/10.3390/jcm13020355
    Crossref
  8. Differences in Brain Atrophy Pattern between People with Multiple Sclerosis and Systemic Diseases with Central Nervous System Involvement Based on Two-Dimensional Linear Measures, Journal of Clinical Medicine, 13, 2, (333), (2024).https://doi.org/10.3390/jcm13020333
    Crossref
  9. Cybersickness in People with Multiple Sclerosis Exposed to Immersive Virtual Reality, Bioengineering, 11, 2, (115), (2024).https://doi.org/10.3390/bioengineering11020115
    Crossref
  10. Predictive Model of Anxiety and Depression Perception in Multiple Sclerosis Patients: Possible Implications for Clinical Treatment, Bioengineering, 11, 1, (100), (2024).https://doi.org/10.3390/bioengineering11010100
    Crossref
  11. See more
Loading...

View Options

Get Access

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

Purchase this article to get full access to it.

Purchase Access, $39 for 24hr of access

View options

Full Text

View Full Text

Media

Figures

Other

Tables

Share

Share

Share article link

Share